SUPPLEMENTARY FIGURE LEGENDS

**Supplementary Figure S1.** Box plot for levels of baseline circulating biomarkers by treatment arms.

**Supplementary Figure S2.** ROC curves of 9-month OS for circulating biomarkers in the ganitumab arm. The AUC was higher for the ratio IGF-2/IGFBP-2 (0.920) than with the individual factors (IGF-2, 0.727; IGFBP-2, 0.772). Similar findings were observed with IGFBP-2 and IGFBP-3: the ratio IGFBP-2/IGFBP-3 had a higher AUC (0.906) than each factor alone (IGFBP-2, 0.772; IGFBP-3, 0.715).